Alteon drops alagebrium in ED

ALT withdrew its IND for the Phase IIa EMERALD trial of alagebrium for erectile dysfunction (ED) and discontinued development in the indication. FDA had placed the trial on clinical hold following a review of preclinical toxicity data that were submitted in August (see BioCentury Extra, Friday Sept. 30, 2005). ALT said additional preclinical testing would have been required to proceed with the trial.

If it can find a partner, ALT will continue to develop the Advanced Glycosylation End-product (A.G.E.) crosslink breaker in heart failure, for which it has completed a Phase IIa trial. Last June, ALT discontinued development of the compound to treat hypertension, for which it had been in Phase IIb testing (see BioCentury Extra, Friday June 10, 2005). ...